Cargando…

Prompt Agalsidase Alfa Therapy Initiation is Associated with Improved Renal and Cardiovascular Outcomes in a Fabry Outcome Survey Analysis

BACKGROUND: The timing of enzyme replacement therapy initiation in patients with Fabry disease is hypothesized to be critical. In this study, we used Fabry Outcome Survey data to assess the impact of prompt versus delayed initiation of treatment with agalsidase alfa on cardiovascular and renal event...

Descripción completa

Detalles Bibliográficos
Autores principales: Hughes, Derralynn, Linhart, Aleš, Gurevich, Andrey, Kalampoki, Vasiliki, Jazukeviciene, Dalia, Feriozzi, Sandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8379390/
https://www.ncbi.nlm.nih.gov/pubmed/34429585
http://dx.doi.org/10.2147/DDDT.S313789
_version_ 1783740995728310272
author Hughes, Derralynn
Linhart, Aleš
Gurevich, Andrey
Kalampoki, Vasiliki
Jazukeviciene, Dalia
Feriozzi, Sandro
author_facet Hughes, Derralynn
Linhart, Aleš
Gurevich, Andrey
Kalampoki, Vasiliki
Jazukeviciene, Dalia
Feriozzi, Sandro
author_sort Hughes, Derralynn
collection PubMed
description BACKGROUND: The timing of enzyme replacement therapy initiation in patients with Fabry disease is hypothesized to be critical. In this study, we used Fabry Outcome Survey data to assess the impact of prompt versus delayed initiation of treatment with agalsidase alfa on cardiovascular and renal events in patients with Fabry disease. METHODS: Available genetic data at baseline were used to define patients with mutations associated with classical versus late-onset Fabry disease. Time to cardiovascular or renal events, from treatment initiation until 120 months, was compared for patients in prompt versus delayed groups. “Prompt” was defined as treatment initiation <24 months from symptom onset (analysis A) or diagnosis (analysis B), and “delayed” was defined as ≥24 months from symptom onset (analysis A) or diagnosis (analysis B). Kaplan–Meier curves and Log rank tests compared event-free probabilities and time to first event. Multivariate Cox regression estimated hazard ratios (HRs). RESULTS: Analysis by time from symptom onset included 1374 patients (172 prompt, 1202 delayed). In a multivariate Cox regression analysis, prompt versus delayed treatment initiation significantly reduced the probability of cardiovascular (HR=0.62; P<0.001) and renal (HR=0.57; P=0.001) events. History of cardiovascular or renal events was associated with increased risk of respective events. Analysis by time from diagnosis included 2051 patients (1006 prompt, 1045 delayed). In a multivariate Cox regression analysis, prompt treatment initiation significantly reduced the probability of cardiovascular events (HR=0.83; P=0.003) after adjusting for history of cardiovascular events, sex, and age at treatment initiation. Univariate analysis showed that the probability of renal events was significantly lower in the prompt group (P=0.018); this finding was attenuated in the multivariate Cox regression analysis. CONCLUSION: This analysis suggests that prompt treatment initiation with agalsidase alfa provided better renal and cardiovascular outcomes than delayed treatment in patients with Fabry disease.
format Online
Article
Text
id pubmed-8379390
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-83793902021-08-23 Prompt Agalsidase Alfa Therapy Initiation is Associated with Improved Renal and Cardiovascular Outcomes in a Fabry Outcome Survey Analysis Hughes, Derralynn Linhart, Aleš Gurevich, Andrey Kalampoki, Vasiliki Jazukeviciene, Dalia Feriozzi, Sandro Drug Des Devel Ther Original Research BACKGROUND: The timing of enzyme replacement therapy initiation in patients with Fabry disease is hypothesized to be critical. In this study, we used Fabry Outcome Survey data to assess the impact of prompt versus delayed initiation of treatment with agalsidase alfa on cardiovascular and renal events in patients with Fabry disease. METHODS: Available genetic data at baseline were used to define patients with mutations associated with classical versus late-onset Fabry disease. Time to cardiovascular or renal events, from treatment initiation until 120 months, was compared for patients in prompt versus delayed groups. “Prompt” was defined as treatment initiation <24 months from symptom onset (analysis A) or diagnosis (analysis B), and “delayed” was defined as ≥24 months from symptom onset (analysis A) or diagnosis (analysis B). Kaplan–Meier curves and Log rank tests compared event-free probabilities and time to first event. Multivariate Cox regression estimated hazard ratios (HRs). RESULTS: Analysis by time from symptom onset included 1374 patients (172 prompt, 1202 delayed). In a multivariate Cox regression analysis, prompt versus delayed treatment initiation significantly reduced the probability of cardiovascular (HR=0.62; P<0.001) and renal (HR=0.57; P=0.001) events. History of cardiovascular or renal events was associated with increased risk of respective events. Analysis by time from diagnosis included 2051 patients (1006 prompt, 1045 delayed). In a multivariate Cox regression analysis, prompt treatment initiation significantly reduced the probability of cardiovascular events (HR=0.83; P=0.003) after adjusting for history of cardiovascular events, sex, and age at treatment initiation. Univariate analysis showed that the probability of renal events was significantly lower in the prompt group (P=0.018); this finding was attenuated in the multivariate Cox regression analysis. CONCLUSION: This analysis suggests that prompt treatment initiation with agalsidase alfa provided better renal and cardiovascular outcomes than delayed treatment in patients with Fabry disease. Dove 2021-08-16 /pmc/articles/PMC8379390/ /pubmed/34429585 http://dx.doi.org/10.2147/DDDT.S313789 Text en © 2021 Hughes et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Hughes, Derralynn
Linhart, Aleš
Gurevich, Andrey
Kalampoki, Vasiliki
Jazukeviciene, Dalia
Feriozzi, Sandro
Prompt Agalsidase Alfa Therapy Initiation is Associated with Improved Renal and Cardiovascular Outcomes in a Fabry Outcome Survey Analysis
title Prompt Agalsidase Alfa Therapy Initiation is Associated with Improved Renal and Cardiovascular Outcomes in a Fabry Outcome Survey Analysis
title_full Prompt Agalsidase Alfa Therapy Initiation is Associated with Improved Renal and Cardiovascular Outcomes in a Fabry Outcome Survey Analysis
title_fullStr Prompt Agalsidase Alfa Therapy Initiation is Associated with Improved Renal and Cardiovascular Outcomes in a Fabry Outcome Survey Analysis
title_full_unstemmed Prompt Agalsidase Alfa Therapy Initiation is Associated with Improved Renal and Cardiovascular Outcomes in a Fabry Outcome Survey Analysis
title_short Prompt Agalsidase Alfa Therapy Initiation is Associated with Improved Renal and Cardiovascular Outcomes in a Fabry Outcome Survey Analysis
title_sort prompt agalsidase alfa therapy initiation is associated with improved renal and cardiovascular outcomes in a fabry outcome survey analysis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8379390/
https://www.ncbi.nlm.nih.gov/pubmed/34429585
http://dx.doi.org/10.2147/DDDT.S313789
work_keys_str_mv AT hughesderralynn promptagalsidasealfatherapyinitiationisassociatedwithimprovedrenalandcardiovascularoutcomesinafabryoutcomesurveyanalysis
AT linhartales promptagalsidasealfatherapyinitiationisassociatedwithimprovedrenalandcardiovascularoutcomesinafabryoutcomesurveyanalysis
AT gurevichandrey promptagalsidasealfatherapyinitiationisassociatedwithimprovedrenalandcardiovascularoutcomesinafabryoutcomesurveyanalysis
AT kalampokivasiliki promptagalsidasealfatherapyinitiationisassociatedwithimprovedrenalandcardiovascularoutcomesinafabryoutcomesurveyanalysis
AT jazukevicienedalia promptagalsidasealfatherapyinitiationisassociatedwithimprovedrenalandcardiovascularoutcomesinafabryoutcomesurveyanalysis
AT feriozzisandro promptagalsidasealfatherapyinitiationisassociatedwithimprovedrenalandcardiovascularoutcomesinafabryoutcomesurveyanalysis
AT promptagalsidasealfatherapyinitiationisassociatedwithimprovedrenalandcardiovascularoutcomesinafabryoutcomesurveyanalysis